Active substanceTaurineTaurine
Similar drugsTo uncover
  • Dibicor®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Dibicor®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Igrele®
    drops d / eye 
    KVADRAT-S, LLC     Russia
  • CardioActiv® Taurine
    pills inwards 
    EVALAR, CJSC     Russia
  • Taurine
    drops d / eye 
  • Taurine
    drops d / eye 
    UPDATE OF PFC, CJSC     Russia
  • Taurine
    drops d / eye 
    VIFITEH, CJSC     Russia
  • Taurine
    solution
    DALHIMFARM, OJSC     Russia
  • Taurine
    drops d / eye 
  • Taurine
    drops d / eye 
    Firm VIPS-MED, LLC     Russia
  • Taurine
    films d / eye 
    Progress RCC, JSC     Russia
  • Taurine
    drops d / eye 
  • Taurine
    drops d / eye 
    Company DEKO, LLC     Russia
  • Taurine
    drops d / eye 
  • Taurin-Akos
    drops d / eye 
    SYNTHESIS, OJSC     Russia
  • Taurin-DIA
    drops d / eye 
  • Taurin-SOLOFARM
    drops d / eye 
    GROTEKS, LLC     Russia
  • Taufon
    drops d / eye 
  • Dosage form: & nbspeye drops
    Composition:

    on 1 liter:

    Active substance:

    Taurine 40 grams

    Excipients: methylparahydroxybenzoate - 1 g

    purified water - up to 1 liter

    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:metabolic means.
    ATX: & nbsp

    S.01.X.A   Other drugs for the treatment of eye diseases

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    An anticancer drug, it has retinoprotective (with subconjunctival administration) and metabolic action. Taurine is a sulfur-containing amino acid, formed in the body in the process of cysteine ​​metabolism.

    It promotes the normalization of the functions of cell membranes, the activation of energy and metabolic processes, the preservation of the electrolyte composition of the cytoplasm due to the accumulation of potassium and calcium cations, and improvement of the conditions for conduction of a nerve impulse.

    Pharmacokinetics:At local application system adsorption is low.
    Indications:

    The drug is used as part of complex therapy. Dystrophy of the cornea; cataracts (senile, diabetic, traumatic, radiation); trauma of the cornea (as a stimulant of reparative processes). Primary open-angle glaucoma (in combination with β-adrenoblockers (to improve the outflow of intraocular fluid).

    Contraindications:HypSensitivity, children's age (up to 18 years).
    Pregnancy and lactation:

    Sufficient experience in the use of the drug during pregnancy and lactation is not present.It is possible to use Taurin for the treatment of pregnant and lactating mothers, but the appointment of a doctor if the expected therapeutic effect for the mother exceeds the risk of developing possible side effects to the fetus.

    Dosing and Administration:

    With cataracts, the drug is prescribed in the form of instillations 1-2 drops 2-4 times a day for 3 months. The course is repeated at a monthly interval.

    In injuries and dystrophic diseases, corneas are used in the same doses for 1 month.

    In open-angle glaucoma (in combination with butylamine hydroxypropoxyphenoxymethyl methyl oxadiazole or timolol maleate) 1-2 drops 2 times in

    day for 15-20 minutes before the appointment of one of the local antihypertensive drugs, for 6 weeks with the subsequent cancellation for 2 weeks.

    Side effects:Allergic reaction.
    Overdose:Data on overdose are absent.
    Interaction:

    Perhaps the combined use of taurine with timolol. The cases of negative drug interaction of taurine with other drugs used in ophthalmology are not described.

    In patients with primary open-angle glaucoma, an increase in the antihypertensive effect of β-adrenoblockers (butyl amino hydroxypropoxyphenoxymethylmethyloxadiazole or timolol maleate) in the case of combined use with taurine.

    Special instructions:

    The preservative contained in the preparation can be irritating to the eye when wearing contact lenses, so any contact lenses should be removed before instillation and put on not earlier than 15 minutes after it. If it is necessary to simultaneously use other ophthalmic drugs (eye drops, etc.), the interval between the use of taurine and other drugs should be at least 10-15 minutes.

    After opening, use within 14 days.

    Effect on the ability to drive transp. cf. and fur:

    Data on the possible negative impact of the drug on the performance of potentially hazardous activities requiring special attention and quick reactions (driving and other vehicles, work
    dispatcher, etc.) are absent.

    Form release / dosage:

    Drops are the main 4%. For 1 ml, 1.5 ml, 2 ml in a dropper with a valve or 5 ml, 10 ml in a dropper tube with a screw neck and polyethylene of high pressure or low-density polyethylene, or polyethylene for medical purposes, or from polyethylene or polypropylene for infusion solutions and main drops.Tube-dropper with a screw neck is capped with screw caps made of polymer materials.

    1 tube of a dropper for 1 ml, 5 ml, 10 ml or 5, 10 tubes of a dropper for 1 ml, 1.5 ml, 2 ml with instructions for use are placed in a cardboard pack.

    Packaging:(1) - a dropper with a valve (1) / instruction manual / - a pack of cardboard
    (1) - a dropper with a valve (10) / instructions for use / - a pack of cardboard
    (1) - a dropper with a valve (5) / instruction manual / - a pack of cardboard
    (10) - drip tube with screw neck (1) / cap screwed on instruction / - cardboard pack
    (2) - a dropper with a valve (10) / instructions for use / - a pack of cardboard
    (2) - a dropper with a valve (5) / instructions for use / - a pack of cardboard
    (5) - drip tube with screw thread (1) / bolt cap screw-in instruction manual / - cardboard pack
    Storage conditions:

    In a place protected from light at a temperature of 2 to 15 ° C. Keep out of the reach of children.

    Shelf life:3 years. Do not use after the expiration date indicated on the packaging.
    Terms of leave from pharmacies:On prescription
    Registration number:LS-002274
    Date of registration:30.08.2011
    The owner of the registration certificate:UPDATE OF PFC, CJSC UPDATE OF PFC, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp03.09.2015
    Illustrated instructions
      Instructions
      Up